Business Context and Reporting Period
Company: Healthcare Acquisition Corp. (Note: Input metadata referenced "Altimmune, Inc.", but the filing text identifies the registrant as Healthcare Acquisition Corp., a Delaware corporation in the development stage).
Reporting Period: Quarterly period ended March 31, 2006.
Business Model: A "blank check" company formed to acquire an operating business in the healthcare industry. The company has not yet consummated a business combination. Substantially all net proceeds from its Initial Public Offering (IPO) are held in a trust fund.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2006 | Inception to Mar 31, 2006 |
|---|---|---|
| Total Revenues | $405,023 | $991,097 |
| Net Income | $204,450 | $481,745 |
| Cash and Cash Equivalents | $1,322,615 | $1,322,615 |
| Cash Held in Trust | $69,124,399 | $69,124,399 |
| Total Current Liabilities | $616,677 | $616,677 |
| Stockholders' Equity | $56,301,858 | $56,301,858 |
| Shares Outstanding | 11,650,000 | 11,650,000 |
Revenue Composition: Revenues consist entirely of interest income ($14,310) and interest/dividend income from the Trust Fund ($390,713).
Expense Composition: Primary expenses include capital-based taxes ($41,168), legal fees ($45,820), and management fees ($22,500).
Material Changes vs. Prior Period
- Liquidity: Cash held in trust increased by approximately $488,330 during the quarter due to interest accumulation, rising from $68,636,069 to $69,124,399.
- Liabilities: Total current liabilities increased from $410,535 (Dec 31, 2005) to $616,677 (Mar 31, 2006). This increase was driven primarily by a rise in deferred revenue ($97,617 increase) and capital-based taxes payable ($41,293 increase).
- Equity: Stockholders' equity increased by $204,450, reflecting the net income for the quarter.
- Operations: The company remains in the development stage with no operating business. Activity is limited to administrative expenses and trust fund management.
Outlook, Risks, and Contingencies
- Liquidation Deadline: The company must consummate a business combination within 18 months of the IPO (August 2005) or 24 months if extension criteria are met. Failure to do so results in mandatory liquidation.
- Redemption Rights: Public stockholders may redeem their shares for a pro-rata portion of the Trust Fund if they vote against a business combination. Approximately 19.99% of the trust fund is classified as "common stock subject to possible redemption."
- Market Risk: The company is not exposed to foreign exchange or commodity risks. Interest rate risk is considered insignificant as trust funds are invested in U.S. Treasury Bills or money market funds.
- Capital Requirements: Management believes funds outside the trust ($1.3 million) are sufficient to operate through August 2007. Additional financing may be required to consummate a business combination.
- Contingencies: The company has agreed to pay a 4% commission to underwriters on warrant exercises solicited more than one year after the IPO. There are no material legal proceedings pending.
Investor Verification Checklist
- Trust Fund Status: Verify the current balance of the Trust Fund ($69.1M) and confirm it remains invested in permitted securities (Treasuries/Money Market) to ensure liquidity for potential redemptions.
- Redemption Liability: Confirm the classification of $13.6 million as "common stock subject to possible redemption" and its impact on net tangible assets.
- Extension Criteria: Review the specific criteria required to extend the 18-month liquidation deadline to 24 months.
- Related Party Transactions: Verify the $7,500 monthly office services fee paid to an affiliate of an Initial Stockholder.
- Warrant Terms: Confirm the exercise price ($6.00) and redemption triggers ($11.50 per share) for the 9.4 million outstanding warrants.